AEON Biopharma, Inc. (AEON) AMEX
0.73
-0.01999897(-2.67%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.73
-0.01999897(-2.67%)
Currency In USD
| Previous Close | 0.75 |
| Open | 0.73 |
| Day High | 0.75 |
| Day Low | 0.73 |
| 52-Week High | 1.45 |
| 52-Week Low | 0.53 |
| Volume | 4,508 |
| Average Volume | 94,490 |
| Market Cap | 8.64M |
| PE | -0.11 |
| EPS | -6.52 |
| Moving Average 50 Days | 0.92 |
| Moving Average 200 Days | 0.95 |
| Change | -0.02 |
AEON Biopharma Appoints John Bencich as Chief Financial Officer
GlobeNewswire Inc.
Mar 09, 2026 8:05 PM GMT
Veteran biotechnology leader with extensive capital markets experience joins AEON as Company advances lead asset through key regulatory milestonesIRVINE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYS
AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting
GlobeNewswire Inc.
Mar 05, 2026 9:05 PM GMT
IRVINE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve ac
AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions
GlobeNewswire Inc.
Jan 21, 2026 9:05 PM GMT
- AEON confirmed that earlier today it held its BPD Type 2a Meeting with the FDA, in line with prior guidance, and is now awaiting official meeting minutes - - Separately, AEON shareholders today voted in favor of the proposals required to complete t